Summary
Cannot verify either claim against the supplied FDA prescribing information because no label text or section citations were provided for the evaluation.
Category Scores
Accurate Statements
Unsupported Statements
Fexofenadine hydrochloride is the salt form used in many products.
No FDA label section number and no label wording/text were provided to support or refute the claim; evaluation states it is 'absent from the label' but provides no label citation.
Allegra is a brand name for fexofenadine.
No FDA label section number and no label wording/text were provided to support or refute the claim; evaluation states it is 'absent from the label' but provides no label citation.
Contradictions
Important Omissions
FDA label citations (section numbers and/or direct label text) corresponding to each claim, or explicit identification of the specific FDA-approved prescribing information document used with the relevant sections.
Importance:
High
Safety Assessment
Potential Patient Risk:
Unknown
The evaluation cannot confirm label alignment due to missing FDA-label citations; therefore safety-impacting accuracy cannot be established from the provided materials.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Missing FDA-approved labeling citations and label text required to verify each claim against the prescribing information.
Suggested Improvement
Provide the specific FDA-approved fexofenadine (Allegra) prescribing information document and cite the exact label sections (with direct wording) for each evaluated claim; if the claim is truly not present, reference the applicable sections or document to justify the 'absent from the label' determination.